Platte River Wealth Advisors LLC reduced its stake in Eli Lilly and Company (NYSE: LLY – Get Rating) by 4.7% in the 1st quarter, Holdings Channel reports. The firm owned 9,060 shares of the company stock after selling 450 shares during the quarter. Eli Lilly and accounts for approximately 0.9% of Platte River Wealth Advisors LLC’s portfolio, making the stock its 25th biggest position. Platte River Wealth Advisors LLC’s holdings in Eli Lilly and were worth $ 2,595,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently made changes to their positions in LLY. Norges Bank acquired a new stake in Eli Lilly and in the 4th quarter valued at $ 2,213,765,000. Capital World Investors boosted its position in Eli Lilly and by 13.9% in the 4th quarter. Capital World Investors now owns 19,115,896 shares of the company stock valued at $ 5,280,206,000 after buying an additional 2,325,514 shares during the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main boosted its position in Eli Lilly and by 38.5% in the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 4,525,748 shares of the company stock valued at $ 1,254,743,000 after buying an additional 1,257,817 shares during the last quarter. State Street Corp boosted its position in Eli Lilly and by 2.5% in the 4th quarter. State Street Corp now owns 33,929,864 shares of the company stock valued at $ 9,372,107,000 after buying an additional 813,983 shares during the last quarter. Finally, Fisher Asset Management LLC boosted its position in Eli Lilly and by 7.2% in the 4th quarter. Fisher Asset Management LLC now owns 6,982,910 shares of the company stock valued at $ 1,928,820,000 after buying an additional 470,522 shares during the last quarter. Hedge funds and other institutional investors own 82.75% of the company stock.
A number of equities analysts have weighed in on the stock. SVB Leerink assumed coverage on shares of Eli Lilly and in a research report on Monday, May 23rd. They issued an “outperform” rating and a $ 341.00 objective price for the company. Mizuho upped their price objective on shares of Eli Lilly and from $ 315.00 to $ 356.00 in a research report on Monday, May 2nd. The Goldman Sachs Group increased their price target on shares of Eli Lilly and from $ 234.00 to $ 264.00 and gave the stock a “neutral” rating in a research report on Tuesday, April 12th. Morgan Stanley increased their price target on shares of Eli Lilly and from $ 364.00 to $ 369.00 in a research report on Friday, April 29th. Finally, Bank of America increased their price target on shares of Eli Lilly and from $ 300.00 to $ 315.00 in a research report on Thursday, March 17th. Three investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $ 311.65.
In related news, CAO Donald A. Zakrowski sold 1,000 shares of the firm’s stock in a transaction that occurred on Wednesday, June 1st. The shares were sold at an average price of $ 313.44, for a total transaction of $ 313,440.00. Following the transaction, the chief accounting officer now owns 6,274 shares in the company, valued at $ 1,966,522.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 2,500 shares of the firm’s stock in a transaction that occurred on Wednesday, March 30th. The shares were sold at an average price of $ 292.03, for a total transaction of $ 730,075.00. The disclosure for this sale can be found here. Insiders sold 1,266,092 shares of company stock worth $ 391,200,768 in the last 90 days. 0.12% of the stock is owned by company insiders.
LLY opened at $ 327.27 on Tuesday. The company 50-day moving average price is $ 298.74 and its 200 day moving average price is $ 277.03. Eli Lilly and Company has a fifty-two week low of $ 220.20 and a fifty-two week high of $ 330.85. The firm has a market cap of $ 310.96 billion, a price-to-earnings ratio of 48.48, a price-to-earnings-growth ratio of 2.26 and a beta of 0.40. The company has a quick ratio of 0.98, a current ratio of 1.27 and a debt-to-equity ratio of 1.60.
Eli Lilly and (NYSE: LLY – Get Rating) last announced its quarterly earnings results on Thursday, April 28th. The company reported $ 2.62 EPS for the quarter, beating the consensus estimate of $ 2.32 by $ 0.30. Eli Lilly and had a net margin of 20.90% and a return on equity of 97.58%. The company had revenue of $ 7.81 billion for the quarter, compared to analyst estimates of $ 7.29 billion. During the same quarter last year, the business earned $ 1.87 earnings per share. Eli Lilly and its revenue was up 14.8% compared to the same quarter last year. Research analysts anticipate that Eli Lilly and Company will post 8.27 earnings per share for the current year.
The company also recently declared a quarterly dividend, which will be paid on Friday, September 9th. Shareholders of record on Monday, August 15th will be paid a $ 0.98 dividend. This represents a $ 3.92 annualized dividend and a dividend yield of 1.20%. Eli Lilly and its payout ratio is currently 58.07%.
Eli Lilly and Profile: (Get Rating)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.
Featured Stories:
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE: LLY – Get Rating).
Receive News & Ratings for Eli Lilly and Daily: – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Eli Lilly and and related companies with MarketBeat.com’s FREE daily email newsletter.
.